Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1

Revista Espanola de Enfermedades Digestivas

Volumn 102, Issue 4, 2010, Pages 234-238

  Cuenca, F ^a   Fernandez C ^a   Devesa, M J ^a   Lopez Alonso G ^a   Mayol, J ^a   Suarez A ^a   Ortega, L ^a   Diaz Rubio M ^a   Ladero, José M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Hepatitis C virus; Pegylated interferon; Predictive factors; Ribavirin; Thyroid hormones

Indexed keywords

CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS TYPING;

EID: 77954980988     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082010000400003     Document Type: Article

References (35)

1. Manns MP, McHutchison JG, Gordon SG, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
2. Fried M, Shiffman M, Reddy R, Smith C, Marinos G, Goncales F, et al. Peginterferon 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Macellin P, et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
4. Lee SS, Bain VG, Peltelkian K, Kradjens M, Yoshida EM, Deschenes M, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397-408.
5. Witthöt Th, Möller B, Wiedmann KH, Mauss St, Link R, Lohmeyer J, et al. Safety, tolerability and efficacy of peginterferon lpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. J Viral Hepatitis 2007; 14: 788-96.
6. Fontanges T, Beorchia S, Douvin C, Delassalle P, Combis J-M, Hanslik B, et al. Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatients setting: prospective analysis of 197 patients with chronic hepatitis C viral infection. Gastroenterol Clin Biol 2007; 31: 566-72.
7. Borroni G, Andreotti M, Casiraghi MA, Ceriani R, Guerzoni P, Omazzi B, et al. Effectiveness of pegylated interferon/ribavirin combination in "real world" patients with chronic hepatitis C (HCV) infection. Aliment Pharmacol Ther 2008; 27: 790-7.
8. Ladero JM, López-Alonso G, Devesa MJ, Cuenca F, Agreda M, Ortega L, et al. The "12 weeks stopping rule" in the treatment of genotype 1 chronic hepatitis C: Two prognostic categories under the same label? Scand J Gastroenterol 2008; 43: 979-83.
9. Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
10. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007; 46: 1688-94.
11. Jensen DM. Individualizing HCV treatment with peginterferon and ribavirin: what needs to be done? Ther Adv Gastroenterol 2009; 2: 5- 10.
12. Bruguera M, Bañres R, Córdoba J, Jardí R, González-Lahoz J, Ladero JM, et al. Documento de consenso de la AEEH sobre el tratamiento de las infecciones por los virus de las hepatitis B y C. Gastroenterol Hepatol 2006; 29 (Supl. 2): 216-30.
13. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 45: 1335-74.
14. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Research 1996; 6: 989-94.
15. Knodell RG, Isaac KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
16. Pellicano R, Puglisi G, Ciancio A, Balzola F, Saracco G, Ciccone G, et al. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? J Med Virol 2008; 80: 628-31.
17. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Peredicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23: 1043-54.
18. Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, et al. Limi- tation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63.
19. Foster GR, Fried MW, Hadziyannis SJ, Mesiger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and rivavirin. Scand J Gastroenterol 2007; 42: 247-55.
20. Mauss S, Hueppe D, Zehnter E, Richter S, Tappe A, Herrmann E. Evaluation of a predictive model of individual chance for sustained virological response in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. J Hepatol 2009; 50 (Supl. 1): S233 (abstract).
21. Craxi A, Piccinino F, Alberti A, Ascione A, Rizzetto M, Iannacone C, et al. Predictors of SVR in naive HCV G1 patients in real life practice: the probe. J Hepatol 2008; 48 (Supl. 2): S291 (abstract).
22. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen CS, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-8.
23. Hernández A, Domper F, Leó A, Lorente R, López B, de la Santa E, et al. Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C. Rev Esp Enferm Dig 2009; 101: 671-9.
24. Ladero JM, Delkader J, Ortega L, Fernández C, Devesa MJ, López-Alonso G, et al. Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: A comparative analysis of 9 scoring methods. Scand J Gastroenterol 2010; 45: 51-9.
25. Forns X, Ampurdanes S, Llovet JM, Aponthe J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
26. Taliani G, Badolato MC, Nigro G, Biasin M, Boddi V, Pasquazzi C, et al. Serum concentration of γGT is a surrogate marker of hepatic TNF-α mRNA expression in chronic hepatitis C. Clin Immunol 2002; 105: 279-85.
27. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of U.S. veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47.
28. Economou M, Milionis H, Filis S, Baltaviannis G, Christou L, Alisaf M, et al. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007; 23: 586-91.
29. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki H, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: aminoacid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
30. Sheridan DA, Price DA, Schmid M, Toms GL, Donaldson P, Neely D, et al. Apolipoprotein B associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus (HCV) infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther 2009; 29: 1282-90.
31. Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinonara Y, Sasaki H, et al. Association between lipoprotein subfraction and the response to hepatitis C treatment in Japanese patients with genotype 1b. J Viral Hepatitis 2009 (epub ahead of print)
32. Angelico F, Francioso S, Del Ben M, Feole K, Carbone M, Pignatelli P, et al. Low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther 2009; 30: 444-51.
33. Romero-Gómez M, Viloria MM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
34. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48: 1753-60.
35. Álvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Reduction in neutrophil count during hepatitis C treatment: drug toxicity or predictor of good response? Dig Dis Sci 2009 Sep 16 [Epub ahead of print].